Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Lethal toxin-equipped effector cells for the potential treatment of cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 16, 2026
Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cells.
Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.
Journal: The Journal of clinical investigation
Published: February 27, 2025
TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.
Journal: Nature cancer
Published: November 14, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
Journal: Science translational medicine
Published: July 10, 2024
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Journal: Nature communications
Published: September 03, 2022
TCR-mimic bispecific antibodies to target the HIV-1 reservoir.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 08, 2022
Author Correction: Targeting public neoantigens for cancer immunotherapy.
Journal: Nature cancer
Published: February 05, 2022
Targeting public neoantigens for cancer immunotherapy.
Journal: Nature cancer
Published: October 22, 2021
Targeting loss of heterozygosity for cancer-specific immunotherapy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 18, 2021
Last Updated: 09/26/2026